Abstract
Abstract There is compelling evidence that alterations in cancer genomes strongly influence clinical responses to anticancer therapies. Indeed, there are now several examples where genomic changes are used as molecular biomarkers to stratify patients most likely to benefit from a treatment (e.g. BRAF in melanoma). Despite these successes, the majority of cancer drugs have not been linked to specific molecular features that could be used to direct their clinical use to maximize patient benefit. We are using pharmacogenomic profiling in a panel of >1,000 cancer cell lines as a biomarker discovery platform by systematically linking pharmacological data with extensive genomic information. I will present results from our most current large-scale analysis of drug screening results as well highlight some the new approaches we have developed to harness clinical sequencing data to guide our analyses. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):CN08-02. Citation Format: Mathew Garnett. Therapeutic biomarker discovery in cancer cells. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr CN08-02.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
